Giá trị hấp thụ tiêu chuẩn của khối u nguyên phát (SUVmax) đo trên 18F-FDG PET/CT và các thành phần NSCLC hỗn hợp tiên đoán sự sống sót ở bệnh nhân ung thư phổi nhỏ tế bào phối hợp được phẫu thuật cắt bỏ
Tóm tắt
Từ khóa
#c-SCLC #SUVmax #TNM stage #prognosis #NSCLCTài liệu tham khảo
Albano D, Bosio G, Treglia G, Giubbini R, Bertagna F (2018) 18F-FDG PET/CT in solitary plasmacytoma: metabolic behavior and progression to multiple myeloma. Eur J Nucl Med Mol Imaging 45:77–84
Babakoohi S, Fu P, Yang M, Linden PA, Dowlati A (2013) Combined SCLC clinical and pathologic characteristics. Clin Lung Cancer 14:113–119
Bai L et al (2017) SUVmax of 18F-FDG PET/CT correlates to expression of major chemotherapy-related tumor markers and serum tumor markers in gastric adenocarcinoma patients. Oncol Rep 37:3433–3440
Bille A et al (2013) The prognostic significance of maximum standardized uptake value of primary tumor in surgically treated non-small-cell lung cancer patients: analysis of 413 cases. Clin Lung Cancer 14:149–156
Brunette LL et al (2018) Predictive value of FDG PET/CT to detect lymph node metastases in cervical cancer. Clin Nucl Med 43:793–801
Burger IA et al (2016) 18F-FDG PET/CT of non-small cell lung carcinoma under neoadjuvant chemotherapy: background-based adaptive-volume metrics outperform TLG and MTV in predicting histopathologic response. J Nucl Med 57:849–854
Chang H, Lee SJ, Lim J, Lee JS, Kim YJ, Lee WW (2019) Prognostic significance of metabolic parameters measured by (18)F-FDG PET/CT in limited-stage small-cell lung carcinoma. J Cancer Res Clin Oncol 145:1361–1367
Chon HJ et al (2019) The clinical implications of FDG-PET/CT differ according to histology in advanced gastric cancer. Gastric Cancer 22:113–122
Du S, Sun H, Gao S, Xin J, Lu Z (2019) Metabolic parameters with different thresholds for evaluating tumor recurrence and their correlations with hematological parameters in locally advanced squamous cell cervical carcinoma: an observational (18)F-FDG PET/CT study. Quant Imaging Med Surg 9:440–452
Fraire AE, Johnson EH, Yesner R, Zhang XB, Spjut HJ, Greenberg SD (1992) Prognostic significance of histopathologic subtype and stage in small cell lung cancer. Hum Pathol 23:520–528
Fushimi H et al (1996) Histologic changes in small cell lung carcinoma after treatment. Cancer 77:278–283
Ha SC et al (2017) Pretreatment tumor SUVmax predicts disease-specific and overall survival in patients with head and neck soft tissue sarcoma. Eur J Nucl Med Mol Imaging 44:33–40
Hage R, Elbers JR, de Brutel RA, van den Bosch JM (1998) Surgery for combined type small cell lung carcinoma. Thorax 53:450–453
Hasbek Z, Ozer H, Erturk SA, Erdiş E, Yucel B, Çiftçi E, Çakmakcilar A (2019) Relationships between hypoxia induced factor-1α and (18)F-FDG PET/CT parameters in colorectal cancer. Rev Esp Med Nucl Imagen Mol 38:355–361
Hsieh CE et al (2018) Pretreatment primary tumor and nodal SUVmax values on 18F-FDG PET/CT images predict prognosis in patients with salivary gland carcinoma. Clin Nucl Med 43:869–879
Hsu HH et al (2016) SUVmax and tumor size predict surgical outcome of synchronous multiple primary lung cancers. Medicine 95:0000000000002351
Kim H, Yoo IR, Boo SH, Park HL, Jh O, Kim SH (2018) Prognostic value of pre- and post-treatment FDG PET/CT parameters in small cell lung cancer patients. Nucl Med Mol Imaging 52:31–38
Kwon SH et al (2016) The Highest Metabolic Activity on FDG PET Is Associated With Overall Survival in Limited-Stage Small-Cell Lung Cancer. Medicine 95:0000000000002772
Lee HY et al (2015) Role of CT and PET imaging in predicting tumor recurrence and survival in patients with lung adenocarcinoma: a comparison with the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification of Lung Adenocarcinoma. J Thorac Oncol 10:1785–1794
Lee SJ, Chung MS, Shin SJ, Choi YY (2018) Correlation of tumor uptake on breast-specific gamma imaging and fluorodeoxyglucose PET/CT with molecular subtypes of breast cancer. Medicine 97:0000000000012840
Lemarignier C, Martineau A, Teixeira L, Vercellino L, Espié M, Merlet P, Groheux D (2017) Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed with (18)F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patients. Eur J Nucl Med Mol Imaging 44:1145–1154
Lu HY et al (2012) Mutation status of epidermal growth factor receptor and clinical features of patients with combined small cell lung cancer who received surgical treatment. Oncol Lett 3:1288–1292
McSorley ST, Khor BY, Tsang K, Colville D, Han S, Horgan PG, McMillan DC (2018) The relationship between (18) F-FDG-PETCT-derived markers of tumour metabolism and systemic inflammation in patients with recurrent disease following surgery for colorectal cancer. Colorectal Dis 20:407–415
Men Y et al (2016) Further understanding of an uncommon disease of combined small cell lung cancer: clinical features and prognostic factors of 114 cases. Chin J Cancer Res 28:486–494
Mirili C et al (2019) Prognostic significance of neutrophil/lymphocyte ratio (NLR) and correlation with PET-CT metabolic parameters in small cell lung cancer (SCLC). Int J Clin Oncol 24:168–178
Moon SW, Seo JH, Jeon HW, Moon MH (2019) Effect of histological subtype and treatment modalities on T1–2 N0–1 small cell lung cancer: a population-based study. Thorac Cancer 10:1229–1240
Nicholson SA et al (2002) Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol 26:1184–1197
Nicholson AG et al (2016) The International Association for the Study of Lung cancer lung cancer staging project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol 11:300–311
Ohashi T et al (2020) The importance of FDG-PET/CT parameters for the assessment of the immune status in advanced HNSCC. Auris Nasus Larynx 20:30022–30025
Okamoto I, Araki J, Suto R, Shimada M, Nakagawa K, Fukuoka M (2006a) EGFR mutation in gefitinib-responsive small-cell lung cancer. Ann Oncol 17:1028–1029
Pankowska V, Malkowski B, Wedrowski M, Wedrowska E, Roszkowski K (2019) FDG PET/CT as a survival prognostic factor in patients with advanced renal cell carcinoma. Clin Exp Med 19:143–148
Park SB et al (2014) Prognostic value of volumetric metabolic parameters measured by [18F]fluorodeoxyglucose-positron emission tomography/computed tomography in patients with small cell lung cancer. Cancer Imaging 14:1470–7330
Park S et al (2016) Correlation between semi-quantitative (18)F-FDG PET/CT Parameters and Ki-67 expression in small cell lung cancer. Nucl Med Mol Imaging 50:24–30
Stinchcombe TE (2017) Current treatments for surgically resectable, limited-stage, and extensive-stage small cell lung cancer. Oncologist 22:1510–1517
Takagi Y, Nakahara Y, Hosomi Y, Hishima T (2013) Small-cell lung cancer with a rare epidermal growth factor receptor gene mutation showing "wax-and-wane" transformation. BMC Cancer 13:1471–2407
Tatematsu A et al (2008) Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res 14:6092–6096
Travis WD (2014) The 2015 WHO classification of lung tumors. Pathologe 2:014–1974
Tsujikawa T et al (2017) (18)F-FDG PET radiomics approaches: comparing and clustering features in cervical cancer. Ann Nucl Med 31:678–685
Veronesi G, Bottoni E, Finocchiaro G, Alloisio M (2015) When is surgery indicated for small-cell lung cancer? Lung Cancer 90:582–589
Wang Y et al (2020) New insight on the correlation of metabolic status on (18)F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging 47:1127–1136
Yu X, Song X, Zhu L, Chen W, Dai D, Li X, Xu W (2017a) Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the diagnosis of newly found suspected malignant solitary pulmonary lesions in patients who have received curative treatment for colorectal cancer. Gastroenterol Res Pract 3458739:12
Yu X et al (2017b) Pretreatment metabolic parameters measured by 18F-FDG-PET to predict the outcome of first-line chemotherapy in extensive-stage small-cell lung cancer. Nucl Med Commun 38:193–200
Zakowski MF, Ladanyi M, Kris MG (2006) EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med 355:213–215
Zer A et al (2016) The Role of 18F-FDG PET/CT on staging and prognosis in patients with small cell lung. Cancer Eur Radiol 26:3155–3161
Zhang C, Yang H, Zhao H, Lang B, Yu X, Xiao P, Zhang X (2017) Clinical outcomes of surgically resected combined small cell lung cancer: a two-institutional experience. J Thorac Dis 9:151–158
Zhao X et al (2019) Surgical resection of SCLC: prognostic factors and the tumor microenvironment. J Thorac Oncol 14:914–923